In this article
Novo Nordisk
on Tuesday launched a multi-month subscription program for its Wegovy obesity drug products that aims to ensure cash-paying patients see lower, “predictable” monthly prices.
Eligible patients can choose between three-, six- or 12-month subscriptions for the Wegovy injection or the two highest doses of the newly launched pill under the same brand name. Longer plans offer lower monthly pricing, and the company expects people to save up to $1,200 a year on the injection and as much as $600 a year on the pill, relative to paying for their individual dose each month, according to a Novo release.
Patients can expect to pay flat monthly prices, even if they move to different doses, the company said. The subscription program will be available starting Tuesday on several of Novo’s telehealth partners, including Ro, WeightWatchers, LifeMD, Sesame and Hims & Hers
